Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02373852Completed

PMS Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention

Role: lead

NCT02780349Not ApplicableCompleted

Evaluation of WIRION™ EPS in Lower Extremities Arteries

Role: lead

NCT01042444Not ApplicableTerminated

Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft

Role: lead

NCT01783639Not ApplicableCompleted

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Role: lead

All 4 trials loaded